Clinical trial
Gemcitabine and Pemetrexed in Primary Unknown Adenocarcinoma
NCT00191503 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00191503 |
|---|---|
| Title | Gemcitabine and Pemetrexed in Primary Unknown Adenocarcinoma |
| Official title | Phase II Study of Gemcitabine and Pemetrexed in Primary Unknown Adenocarcinoma |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adenocarcinoma |
| Intervention type | Drug |
| Interventions | Pemetrexed, Gemcitabine |
| Enrollment | 30 |
| Start date | Jan 1, 2005 |
| Completion | Nov 1, 2005 |
| First posted | Sep 19, 2005 |
| Last update posted | Jan 26, 2007 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: